GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease

Diabetes Metab J. 2012 Aug;36(4):262-7. doi: 10.4093/dmj.2012.36.4.262. Epub 2012 Aug 20.


Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.

Keywords: Fatty acid oxidation; Glucagon-like peptide 1; Non-alcoholic fatty liver disease.